TRACON Pharmaceuticals (TCON) Receives Daily Coverage Optimism Rating of 0.19

Media headlines about TRACON Pharmaceuticals (NASDAQ:TCON) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. TRACON Pharmaceuticals earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.8459657164195 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:

How to Become a New Pot Stock Millionaire

Separately, Zacks Investment Research cut TRACON Pharmaceuticals from a “buy” rating to a “hold” rating and set a $4.00 price objective on the stock. in a research report on Friday, January 5th.

TRACON Pharmaceuticals stock opened at $2.55 on Friday. TRACON Pharmaceuticals has a one year low of $2.00 and a one year high of $4.10. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.06 and a current ratio of 3.06. The firm has a market cap of $50.59, a P/E ratio of -2.24 and a beta of 2.08.

TRACON Pharmaceuticals (NASDAQ:TCON) last posted its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09. TRACON Pharmaceuticals had a negative return on equity of 96.65% and a negative net margin of 201.21%. equities analysts anticipate that TRACON Pharmaceuticals will post -0.91 EPS for the current fiscal year.

In other news, major shareholder Enterprise Associates 14 New bought 707,964 shares of the stock in a transaction on Tuesday, March 27th. The shares were bought at an average price of $2.70 per share, with a total value of $1,911,502.80. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.30% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).

Insider Buying and Selling by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)

Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply